Advancements in Patient-Centered Care

Operationalizing Outpatient Bispecific Therapy: Practical Considerations for Safe and Sustainable Implementation

October 6, 2026

58% of surveyed oncology professionals report delivering bispecific step-up dosing in the outpatient setting. But what does it take to do it safely? In a new NCODA white paper, Tara Graff, DO, MS, explores insights from 126 oncology professionals on the real-world challenges and practical considerations for implementing outpatient bispecific T-cell engager (BTCE) programs.

Insurance Barriers in Cancer Care: A Care Partner’s Perspective

October 7, 2026

A care partner shares how insurance denials disrupted her husband’s cancer care and calls for timely access to the care physicians recommend.

Integrating Sexual Health Into Prostate Cancer Care: Perspectives from Patients, Care Partners, and Healthcare

October 6, 2026

Sexual health matters in prostate cancer care, yet 44% of patients surveyed said they started the conversation themselves. NCODA’s latest white paper explores concerns beyond erectile dysfunction and practical ways care teams can address them.

Step Therapy in Cancer Care: A Patient’s Perspective

September 30, 2026

Paul O’Hara shares how step therapy complicated access to his prescribed leukemia treatment and calls for reforms that put cancer treatment decisions in physicians’ hands.

Temporary Importation of Ifosfamide Announced Amid Critical U.S. Shortage

September 23, 2026

Temporarily imported ifosfamide is now shipping to U.S. treatment centers amid a critical shortage, and oncology teams should review its differences from the FDA-approved product before ordering or use.

NCODA Featured in Specialty Pharmacy Continuum on Medically Integrated Oncology Pharmacy

September 2, 2026

NCODA’s Jonas Congelli discusses the patient-care benefits and evolving future of medically integrated oncology pharmacy in Specialty Pharmacy Continuum.

Expanding Access to CAR-T Therapy Operational Models and Best Practices Across the Oncology Care Continuum

September 2, 2026

The landscape for chimeric antigen receptor T-cell (CAR-T) therapy is evolving, with growing use in earlier lines of treatment, expanding outpatient administration, and a widening range of practice settings taking on delivery. But translating these advances into everyday practice can bring real operational, logistical, and coordination challenges.

Shifting Treatment Perspectives in Polycythemia Vera Real-World Experience with Ropeginterferon Alfa-2b

August 21, 2026

The treatment landscape for polycythemia vera (PV) is evolving, with growing emphasis on long-term disease control, earlier use of interferon-based therapy, and individualized treatment strategies. But translating these advances into everyday practice can bring real operational and patient-care challenges.

NCODA Urges CMS to Reconsider Proposed QSSD Policy for Fixed-Combination New Formulations

NCODA has submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding its proposed policy for the treatment of certain fixed-combination new formulations under the Medicare Drug Price Negotiation Program.

Keeping Cancer Care Close to Home

August 4, 2026

NCODA Associate Executive Director Jonas Congelli joins oncology leaders in examining access barriers, practice sustainability, and what it takes to keep advanced cancer care close to home.